Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 02, 2022 20:30 ET | Source: Aequus Pharmaceuticals

Aequus Announces Delay in Filing Annual Financial Statements

VANCOUVER, British Columbia, May 02, 2022 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”) announces that the filing of its audited annual...
May 02, 2022 08:00 ET | Source: Aequus Pharmaceuticals

Aequus Announces Short Term Loan

VANCOUVER, British Columbia, May 02, 2022 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”) announces that it has entered into an agreement with...
April 22, 2022 16:30 ET | Source: Aequus Pharmaceuticals

Aequus Announces Director Resignation

VANCOUVER, British Columbia, April 22, 2022 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF), a specialty pharmaceutical company with a focus on developing, advancing and...
January 24, 2022 08:00 ET | Source: Aequus Pharmaceuticals

Aequus Extends Commercial Agreement for Specialty Product Tacrolimus IR in Canada

VANCOUVER, British Columbia, Jan. 24, 2022 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), announced today that it has agreed to an extension...
January 11, 2022 09:00 ET | Source: Aequus Pharmaceuticals

Sandoz and Aequus Agree to 1-Year Extension on Vistitan in Canada

VANCOUVER, British Columbia, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on...
January 06, 2022 09:00 ET | Source: Aequus Pharmaceuticals

Aequus Announces Canadian Filing of NDS for Preservative-Free Glaucoma Medication

Health Canada Submission of Preservative-Free Prescription ‘Zimed PF’ Accepted for Screening VANCOUVER, British Columbia, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS,...
November 03, 2021 05:00 ET | Source: Aequus Pharmaceuticals

Aequus Reports Third Quarter 2021 Financial Highlights

VANCOUVER, British Columbia, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on...
August 30, 2021 08:00 ET | Source: Aequus Pharmaceuticals

Aequus Reports Second Quarter 2021 Financial Highlights

VANCOUVER, British Columbia, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on...
August 25, 2021 08:00 ET | Source: Aequus Pharmaceuticals

Aequus Strengthens Clinical Experience in Stargardt Disease with Pediatric Ophthalmology Expertise

VANCOUVER, British Columbia, Aug. 25, 2021 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus”) a speciality pharmaceutical company, is pleased to announce that Dr....
August 17, 2021 08:00 ET | Source: Aequus Pharmaceuticals

Aequus and reVision to Collaborate on Stargardt Disease Program

VANCOUVER, British Columbia and RIDGEWOOD, N.J., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus”) and reVision Therapeutics, Inc. (“reVision”)...